Equities analysts expect China Biologic Products Holdings Inc (NASDAQ:CBPO) to announce earnings of $0.70 per share for the current quarter, Zacks reports. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $0.76 during the same quarter last year, which suggests a negative year over year growth rate of 7.9%. The company is expected to issue its next quarterly earnings report on Wednesday, March 4th.
On average, analysts expect that China Biologic Products will report full-year earnings of $4.17 per share for the current financial year, with EPS estimates ranging from $3.94 to $4.40. For the next year, analysts forecast that the business will report earnings of $4.38 per share, with EPS estimates ranging from $4.30 to $4.45. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for China Biologic Products.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, November 13th. The biopharmaceutical company reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.52. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm had revenue of $136.10 million for the quarter. During the same period in the previous year, the firm posted $0.96 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis.
Several institutional investors and hedge funds have recently bought and sold shares of CBPO. York Capital Management Global Advisors LLC grew its holdings in China Biologic Products by 13.9% during the 2nd quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock worth $107,567,000 after acquiring an additional 137,484 shares during the last quarter. Vanguard Group Inc. grew its holdings in China Biologic Products by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock worth $90,575,000 after acquiring an additional 29,178 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in China Biologic Products by 18.1% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 129,445 shares of the biopharmaceutical company’s stock worth $14,818,000 after acquiring an additional 19,846 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in China Biologic Products during the 2nd quarter worth about $8,749,000. Finally, Point72 Asset Management L.P. bought a new stake in China Biologic Products during the 2nd quarter worth about $6,477,000. 37.05% of the stock is currently owned by institutional investors and hedge funds.
CBPO traded up $0.30 on Tuesday, reaching $117.00. 71,900 shares of the company traded hands, compared to its average volume of 85,168. The company has a market cap of $4.59 billion, a price-to-earnings ratio of 29.10, a PEG ratio of 7.09 and a beta of 1.18. China Biologic Products has a 52-week low of $70.30 and a 52-week high of $119.44. The stock’s 50 day moving average price is $115.09 and its 200-day moving average price is $100.98.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.